Search

Your search keyword '"Bansal, Radhika"' showing total 331 results
Start Over Author "Bansal, Radhika"
331 results on '"Bansal, Radhika"'

3. A Framework for Ranking Content Providers Using Prompt Engineering and Self-Attention Network

Author

Siddiqi, Gosuddin Kamaruddin, Shah, Deven Santhosh, Bansal, Radhika, and Kamalov, Askar

Subjects
Computer Science - Information Retrieval
Abstract

This paper addresses the problem of ranking Content Providers for Content Recommendation System. Content Providers are the sources of news and other types of content, such as lifestyle, travel, gardening. We propose a framework that leverages explicit user feedback, such as clicks and reactions, and content-based features, such as writing style and frequency of publishing, to rank Content Providers for a given topic. We also use language models to engineer prompts that help us create a ground truth dataset for the previous unsupervised ranking problem. Using this ground truth, we expand with a self-attention based network to train on Learning to Rank ListWise task. We evaluate our framework using online experiments and show that it can improve the quality, credibility, and diversity of the content recommended to users.

Published
2024

5. Local Life: Stay Informed Around You, A Scalable Geoparsing and Geotagging Approach to Serve Local News Worldwide

Author

Shah, Deven Santosh, Siddiqi, Gosuddin Kamaruddin, He, Shiying, and Bansal, Radhika

Subjects
Computer Science - Information Retrieval
Abstract

Local news has become increasingly important in the news industry due to its various benefits. It offers local audiences information that helps them participate in their communities and interests. It also serves as a reliable source of factual reporting that can prevent misinformation. Moreover, it can influence national audiences as some local stories may have wider implications for politics, environment or crime. Hence, detecting the exact geolocation and impact scope of local news is crucial for news recommendation systems. There are two fundamental things required in this process, (1) classify whether an article belongs to local news, and (2) identify the geolocation of the article and its scope of influence to recommend it to appropriate users. In this paper, we focus on the second step and propose (1) an efficient approach to determine the location and radius of local news articles, (2) a method to reconcile the user's location with the article's location, and (3) a metric to evaluate the quality of the local news feed. We demonstrate that our technique is scalable and effective in serving hyperlocal news to users worldwide., Comment: 7 pages, 3 figures, 3 tables

Published
2023

6. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions

Author

Major, Ajay, Yu, Jovian, Shukla, Navika, Che, Yan, Karrison, Theodore G, Treitman, Rachel, Kamdar, Manali K, Haverkos, Bradley M, Godfrey, James, Babcook, Melissa A, Voorhees, Timothy J, Carlson, Sophie, Gaut, Daria, Oliai, Caspian, Romancik, Jason T, Winter, Allison M, Hill, Brian T, Bansal, Radhika, Bisneto, Jose C Villasboas, Nizamuddin, Imran A, Karmali, Reem, Fitzgerald, Lindsey A, Stephens, Deborah M, Pophali, Priyanka A, Trabolsi, Asaad, Schatz, Jonathan H, Hu, Marie, Bachanova, Veronika, Slade, Michael J, Singh, Nathan, Ahmed, Nausheen, McGuirk, Joseph P, Bishop, Michael R, Riedell, Peter A, and Kline, Justin

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Immunology, Clinical Research, Hematology, Rare Diseases, Lymphoma, Cancer, Biotechnology, Humans, Receptors, Chimeric Antigen, Retrospective Studies, Neoplasm Recurrence, Local, Lymphoma, Large B-Cell, Diffuse, Immunotherapy, Adoptive, Cardiovascular medicine and haematology
Abstract

Checkpoint inhibitor (CPI) therapy with anti-PD-1 antibodies has been associated with mixed outcomes in small cohorts of patients with relapsed aggressive B-cell lymphomas after CAR-T failure. To define CPI therapy efficacy more definitively in this population, we retrospectively evaluated clinical outcomes in a large cohort of 96 patients with aggressive B-cell lymphomas receiving CPI therapy after CAR-T failure across 15 US academic centers. Most patients (53%) had diffuse large B-cell lymphoma, were treated with axicabtagene ciloleucel (53%), relapsed early (≤180 days) after CAR-T (83%), and received pembrolizumab (49%) or nivolumab (43%). CPI therapy was associated with an overall response rate of 19% and a complete response rate of 10%. Median duration of response was 221 days. Median progression-free survival (PFS) and overall survival (OS) were 54 and 159 days, respectively. Outcomes to CPI therapy were significantly improved in patients with primary mediastinal B-cell lymphoma. PFS (128 vs 51 days) and OS (387 vs 131 days) were significantly longer in patients with late (>180 days) vs early (≤180 days) relapse after CAR-T. Grade ≥3 adverse events occurred in 19% of patients treated with CPI. Most patients (83%) died, commonly because of progressive disease. Only 5% had durable responses to CPI therapy. In the largest cohort of patients with aggressive B-cell lymphoma treated with CPI therapy after CAR-T relapse, our results reveal poor outcomes, particularly among those relapsing early after CAR-T. In conclusion, CPI therapy is not an effective salvage strategy for most patients after CAR-T, where alternative approaches are needed to improve post-CAR-T outcomes.

Published
2023

7. Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management

Author

Khurana, Arushi, Rosenthal, Allison C., Mohty, Razan, Gaddam, Mamatha, Bansal, Radhika, Hathcock, Matthew A., Nedved, Adrienne N., Durani, Urshila, Iqbal, Madiha, Wang, Yucai, Paludo, Jonas, Villasboas, J. C., Dingli, David, Kourelis, Taxiarchis, Leung, Nelson, Alkhateeb, Hassan, Ruff, Michael W., Gallo de Moraes, Alice, Vergidis, Paschalis, Herrmann, Joerg, Kenderian, Saad S., Bennani, N. Nora, Johnston, Patrick B., Ansell, Stephen M., and Lin, Yi

Published
2024
Full Text
View/download PDF

8. Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma

Author

Rees, Matthew J., Mammadzadeh, Aytaj, Bolarinwa, Abiola, Elhaj, Mohammed E., Bohra, Arwa, Bansal, Radhika, Ailawadhi, Sikander, Parrondo, Ricardo, Chhabra, Saurabh, Khot, Amit, Hayman, Suzanne, Dispenzieri, Angela, Buadi, Francis, Dingli, David, Warsame, Rahma, Kapoor, Prashant, Gertz, Morie A., Muchtar, Eli, Kourelis, Taxiarchis, Gonsalves, Wilson, Rajkumar, S. Vincent, Lin, Yi, and Kumar, Shaji

Published
2024
Full Text
View/download PDF

10. What's happening in your neighborhood? A Weakly Supervised Approach to Detect Local News

Author

Shah, Deven Santosh, He, Shiying, Siddiqi, Gosuddin Kamaruddin, and Bansal, Radhika

Subjects
Computer Science - Information Retrieval, Computer Science - Computation and Language, Computer Science - Machine Learning
Abstract

Local news articles are a subset of news that impact users in a geographical area, such as a city, county, or state. Detecting local news (Step 1) and subsequently deciding its geographical location as well as radius of impact (Step 2) are two important steps towards accurate local news recommendation. Naive rule-based methods, such as detecting city names from the news title, tend to give erroneous results due to lack of understanding of the news content. Empowered by the latest development in natural language processing, we develop an integrated pipeline that enables automatic local news detection and content-based local news recommendations. In this paper, we focus on Step 1 of the pipeline, which highlights: (1) a weakly supervised framework incorporated with domain knowledge and auto data processing, and (2) scalability to multi-lingual settings. Compared with Stanford CoreNLP NER model, our pipeline has higher precision and recall evaluated on a real-world and human-labeled dataset. This pipeline has potential to more precise local news to users, helps local businesses get more exposure, and gives people more information about their neighborhood safety., Comment: 8 pages, 2 figures, 5 tables

Published
2023

11. Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience.

Author

Kourelis, Taxiarchis, Bansal, Radhika, Berdeja, Jesus, Siegel, David, Patel, Krina, Mailankody, Sham, Htut, Myo, Wong, Sandy, Sidana, Surbhi, Cowan, Andrew, Alsina, Melissa, Cohen, Adam, Holstein, Sarah, Bergsagel, Leif, Ailawadhi, Sikander, Raje, Noopur, Dhakal, Binod, Rossi, Adriana, Lin, Yi, and Shah, Nina

Subjects
Access, CAR T cells, Multiple myeloma, Humans, Receptors, Chimeric Antigen, Multiple Myeloma, T-Lymphocytes, B-Cell Maturation Antigen, Immunotherapy, Adoptive
Abstract

Chimeric antigen receptor T cell (CAR-T) therapies are Food and Drug Administration (FDA)-approved for patients with triple refractory multiple myeloma (MM). Real-world access to CAR-T therapy remains challenging owing to supply chain limitations impacting manufacturing. The goal of this study was to evaluate the extent of this issue and how major centers are handling the challenges of CAR-T manufacturing slot allocation. MM CAR-T physician leaders at each CAR-T treatment center across the United States were surveyed. We received responses from 17 of 20 centers. A median of 1 slot is allocated per month per center, and the median number of patients per center on the waitlist since the FDAs approval of idecabtagene vicleucel is 20 (range, 5 to 100). As a result, patients remain on the waitlist for a median of 6 months (range, 2 to 8 months) prior to leukapheresis. For patient selection, all centers reported using a committee of experienced CAR-T physicians to ensure consistency. To ensure transparency, 15 centers make selection criteria, selection timelines, and priority scores readily available for CAR-T providers. Centers also reported using ethical values for selection: (1) equal treatment: time spent on waiting list (n = 12); (2) priority to the worst-off: limited therapeutic options (n = 14), MM burden (n = 11), high Hematopoietic Cell Transplantation Comorbidity Index (n = 5); (3) maximize benefit: most likely to complete apheresis (n = 13) or infusion (n = 13) or to achieve response (n = 8); and (4) social value: younger patients (n = 3). Maximizing benefit was considered the most important criterion by 10 centers. This study is the first attempt to evaluate existing issues with CAR-T access for patients with MM and the variability and challenges in patient selection. Integrating ethical resource allocation strategies, similar to those described here, into formal institutional policies would help streamline access to CAR-T therapy and protect the needs of both current and future patients and physicians.

Published
2023

12. Outcomes of patients with R/R B-cell NHL and limited (

Author

Saifi, Omran, Breen, William G., Lester, Scott C., Rule, William G., Stish, Bradley J., Rosenthal, Allison, Munoz, Javier, Lin, Yi, Bansal, Radhika, Hathcock, Matthew A., Johnston, Patrick B., Ansell, Stephen M., Paludo, Jonas, Khurana, Arushi, Villasboas, Jose C., Wang, Yucai, Iqbal, Madiha, Alhaj Moustafa, Muhamad, Murthy, Hemant S., Ayala, Ernesto, Kharfan-Dabaja, Mohamed A., Hoppe, Bradford S., and Peterson, Jennifer L.

Published
2024
Full Text
View/download PDF

13. Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity

Author

Breen, William G., Young, Jason R., Hathcock, Matthew A., Kowalchuk, Roman O., Thorpe, Matthew P., Bansal, Radhika, Khurana, Arushi, Bennani, N. Nora, Paludo, Jonas, Bisneto, Jose Villasboas, Wang, Yucai, Ansell, Stephen M., Peterson, Jennifer L., Johnston, Patrick B., Lester, Scott C., and Lin, Yi

Published
2023
Full Text
View/download PDF

14. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma

Author

Rejeski, Kai, Hansen, Doris K., Bansal, Radhika, Sesques, Pierre, Ailawadhi, Sikander, Logue, Jennifer M., Bräunlein, Eva, Cordas dos Santos, David M., Freeman, Ciara L., Alsina, Melissa, Theurich, Sebastian, Wang, Yucai, Krackhardt, Angela M., Locke, Frederick L., Bachy, Emmanuel, Jain, Michael D., Lin, Yi, and Subklewe, Marion

Published
2023
Full Text
View/download PDF

18. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

Author

Sidana, Surbhi, Patel, Krina K., Peres, Lauren C., Bansal, Radhika, Kocoglu, Mehmet H., Shune, Leyla, Atrash, Shebli, Smith, Kinaya, Midha, Shonali, Ferreri, Christopher, Dhakal, Binod, Dima, Danai, Costello, Patrick, Wagner, Charlotte, Reshef, Ran, Hosoya, Hitomi, Mikkilineni, Lekha, Atanackovic, Djordje, Chhabra, Saurabh, Parrondo, Ricardo, Nadeem, Omar, Mann, Hashim, Kalariya, Nilesh, Hovanky, Vanna, De Avila, Gabriel, Freeman, Ciara L., Locke, Frederick L., Alsina, Melissa, Wong, Sandy, Herr, Megan, Htut, Myo, McGuirk, Joseph, Sborov, Douglas W., Khouri, Jack, Martin, Thomas, Janakiram, Murali, Lin, Yi, and Hansen, Doris K.

Published
2024
Full Text
View/download PDF

19. Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma

Author

Saifi, Omran, Breen, William G., Lester, Scott C., Rule, William G., Stish, Bradley J., Rosenthal, Allison, Munoz, Javier, Lin, Yi, Bansal, Radhika, Hathcock, Matthew A., Bennani, N. Nora, Paludo, Jonas, Khurana, Arushi, Villasboas, Jose C., Johnston, Patrick B., Ansell, Stephen M., Iqbal, Madiha, Moustafa, Muhamad Alhaj, Murthy, Hemant S., Kharfan-Dabaja, Mohamed A., Hoppe, Bradford S., and Peterson, Jennifer L.

Published
2023
Full Text
View/download PDF

20. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma

Author

Wiedmeier-Nutor, Julia E., Iqbal, Madiha, Rosenthal, Allison C., Bezerra, Evandro D., Garcia-Robledo, Juan Esteban, Bansal, Radhika, Johnston, Patrick B., Hathcock, Matthew, Larsen, Jeremy T., Bergsagel, P. Leif, Wang, Yucai, Reeder, Craig B., Leis, Jose F., Fonseca, Rafael, Palmer, Jeanne M., Gysbers, Brianna J., Mwangi, Raphael, Warsame, Rahma M., Kourelis, Taxiarchis, Hayman, Suzanne R., Dingli, David, Kapoor, Prashant, Kumar, Shaji K., Durani, Urshila, Villasboas, Jose C., Paludo, Jonas, Bennani, N. Nora, Nowakowski, Grzegorz, Ansell, Stephen M., Castro, Januario E, Kharfan-Dabaja, Mohamed A., Lin, Yi, Vergidis, Paschalis, Murthy, Hemant S., and Munoz, Javier

Published
2023
Full Text
View/download PDF

21. Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report

Author

Desai, Aakash, Rakshit, Sagar, Bansal, Radhika, Ashara, Yash, Potter, Ashley, Manochakian, Rami, Lou, Yanyan, Zhao, Yujie, Ernani, Vinicius, Savvides, Panos, Schwecke, Anna, Moffett, Nicole, Hocum, Craig, Leventakos, Konstantinos, Adjei, Alex, Marks, Randolph, Molina, Julian, Mansfield, Aaron S., Chen, Zong-Ming, and Dimou, Anastasios

Published
2023
Full Text
View/download PDF

23. Metformin and cytokine release syndrome after immune effector cell therapy.

Author

Mammadzadeh, Aytaj, primary, Bansal, Radhika, additional, Alkhateeb, Hassan B., additional, Ansell, Stephen M., additional, Bennani, Nabila Nora, additional, Binder, Moritz, additional, Cook, Joselle, additional, Durani, Urshila, additional, Gertz, Morie A., additional, Hampel, Paul Joseph, additional, Hayman, Suzanne R., additional, Johnston, Patrick B., additional, Kapoor, Prashant, additional, Kenderian, Saad, additional, Khurana, Arushi, additional, Kumar, Shaji, additional, Kourelis, Taxiarchis, additional, Lin, Yi, additional, Paludo, Jonas, additional, and Dingli, David, additional

Published
2024
Full Text
View/download PDF

24. Factors before leukapheresis that correlate with severe cytopenia and therapy related myeloid neoplasm post CAR-T.

Author

De Menezes Silva Corraes, Andre, primary, Baranwal, Anmol, additional, Bansal, Radhika, additional, Gurney, Mark, additional, Rosenthal, Allison Claire, additional, Kharfan-Dabaja, Mohamed, additional, Khurana, Arushi, additional, Johnston, Patrick B., additional, Ansell, Stephen M., additional, Kapoor, Prashant, additional, Gertz, Morie A., additional, Kumar, Shaji, additional, Dingli, David, additional, Durani, Urshila, additional, Villasboas Bisneto, Jose, additional, Kenderian, Saad, additional, Alkhateeb, Hassan B., additional, Wang, Yucai, additional, Shah, Mithun Vinod, additional, and Lin, Yi, additional

Published
2024
Full Text
View/download PDF

25. Class comparison of BCMA-directed therapies in relapsed multiple myeloma.

Author

Matthew, Rees J., primary, Mammadzadeh, Aytaj, additional, Bolarinwa, Abiola, additional, Elhaj, Mohammed E, additional, Bohra, Arwa, additional, Ailawadhi, Sikander, additional, Parrondo, Ricardo, additional, Chhabra, Saurabh, additional, Lin, Yi, additional, Binder, Moritz, additional, Hayman, Suzanne R., additional, Dispenzieri, Angela, additional, Buadi, Francis, additional, Dingli, David, additional, Warsame, Rahma M., additional, Bansal, Radhika, additional, Kapoor, Prashant, additional, Gertz, Morie A., additional, Muchtar, Eli, additional, and Kumar, Shaji, additional

Published
2024
Full Text
View/download PDF

26. Real world outcome of patients with multiple myeloma who received bispecific antibodies after CAR-T therapy.

Author

Bansal, Radhika, primary, De Menezes Silva Corraes, Andre, additional, Brunaldi, Larissa, additional, Sandahl, Tyler B, additional, Matthew, Rees J, additional, Hayman, Suzanne R., additional, Binder, Moritz, additional, Abdallah, Nadine, additional, Dingli, David, additional, Cook, Joselle, additional, Gertz, Morie A., additional, Kapoor, Prashant, additional, Kourelis, Taxiarchis, additional, Warsame, Rahma M., additional, Kumar, Shaji, additional, and Lin, Yi, additional

Published
2024
Full Text
View/download PDF

30. Serial Evaluation of Preimmunization Antibody Titers in Lymphoma Patients Receiving Chimeric Antigen Receptor T Cell Therapy

Author

Bansal, Radhika, primary, Vergidis, Paschalis, additional, Tosh, Pritish K., additional, Wilson, John, additional, Hathcock, Matthew, additional, Khurana, Arushi, additional, Bennani, N. Nora, additional, Paludo, Jonas, additional, Villasboas, Jose C., additional, Wang, Yucai, additional, Ansell, Stephen M., additional, Johnston, Patrick B., additional, Freeman, Catherine, additional, and Lin, Yi, additional

Published
2024
Full Text
View/download PDF

32. Outpatient Management of CAR-T and Teclistamab for Patients with Lymphoma and Multiple Myeloma

Author

Bansal, Radhika, primary, Paludo, Jonas, additional, Corraes, Andre De Menezes Silva, additional, Spychalla, Megan, additional, Sandahl, Tyler B., additional, Haugen, Kelsey, additional, Khurana, Arushi, additional, Hampel, Paul, additional, Durani, Urshila, additional, Dingli, David, additional, Hayman, Suzanne R, additional, Kapoor, Prashant, additional, Wang, Yucai, additional, Binder, Moritz, additional, Kenderian, Saad S., additional, Kourelis, Taxiarchis, additional, Kumar, Shaji, additional, Warsame, Rahma, additional, Bennani, Dr. N. Nora, additional, Gertz, Morie, additional, Johnston, Patrick B, additional, Ansell, Stephen, additional, and Lin, Yi, additional

Published
2024
Full Text
View/download PDF

34. Contributors

Author

Abbas, Ghulam, primary, Adeel, Muhammad, additional, Aftab, Tariq, additional, Afza, Nishat, additional, Afzal, Shadma, additional, Ahmad, Shakeel, additional, Ahmad, Zahoor, additional, Akhter, Sohail, additional, Ali, Mohammad Eyakub, additional, Ali, Sahin, additional, Ali, Zulfiqar, additional, Amin, Huma, additional, Anil, Ajin S., additional, Anjum, Mohsina, additional, Banerjee, Aditya, additional, Banerjee, Amrita, additional, Bansal, K.C., additional, Bansal, Radhika, additional, Bashir, Muhammad Amjad, additional, Behera, Laxmipreeya, additional, Bhadra, Preetha, additional, Bhatta, Bishal Binaya, additional, Bhattacharyya, Samrat, additional, Bhutia, Karma L., additional, Brestic, Marian, additional, Chandan, Kumari, additional, Chandra, Kailash, additional, Chaudhary, Nidhi, additional, Chauhan, Jyoti, additional, Choudhury, Sourav, additional, Dash, Deepali, additional, Datta, Diptanu, additional, Devedee, Anoop Kumar, additional, Dey, Prajjal, additional, Dutta, Asik, additional, Goel, Sonia, additional, Gorovtsov, Andrey, additional, Hassan, Mohamed M., additional, Hassan, Zeshan, additional, Hidangmayum, Akash, additional, Hossain, Akbar, additional, Hussain, Mubshar, additional, Ijaz, Muhammad, additional, Iqbal, Muhammad Munir, additional, Islam, Tanjina, additional, Islam, Tofazzal, additional, Jamil, Shakra, additional, Jatav, Hanuman Singh, additional, Kanwal, Shamsa, additional, Khan, Asif Ali, additional, Khan, Azhar Abbas, additional, Khan, Zulqurnain, additional, Kumari, Aradhna, additional, Kumari, Asha, additional, Kundu, Arnab, additional, Maitra, Sagar, additional, Mallick, Payel, additional, Manzoor, Zahid, additional, Mishra, Udit Nandan, additional, Mohapatra, Kiran Kumar, additional, Moulik, Debjyoti, additional, Nisar, Amina, additional, Panda, Darshan, additional, Pandey, Himanshu, additional, Pandita, Deepu, additional, Parida, Selukash, additional, Patra, Abhik, additional, Patra, Kiranmay, additional, Pattnaik, Debasish, additional, Praharaj, Subhashisa, additional, Pramanick, Biswajit, additional, Rahman, Md. Muzahid E., additional, Rajput, Vishnu D., additional, Raza, Hafiz Muhammad Ali, additional, Raza, Qurat-Ul-Ain, additional, Rehim, Abdur, additional, Rekwar, Ravindra Kumar, additional, Roy, Somnath, additional, Roychoudhury, Aryadeep, additional, Sadhukhan, Rahul, additional, Saha, Debanjana, additional, Sahoo, Sanjib Kumar, additional, Sarwat, Maryam, additional, Sathyanarayana, Eetela, additional, Sattar, Abdul, additional, Sen, Suman, additional, Shahzad, Rahil, additional, Shahzad, Umbreen, additional, Shankar, Tanmoy, additional, Sharma, Binny, additional, Sharma, Deepa, additional, Sharma, Laimayum Devarishi, additional, Sher, Ahmad, additional, Singh, Ankur, additional, Singh, Bansh Narayan, additional, Singh, Manish P., additional, Singh, Nand K., additional, Singh, Santosh Kumar, additional, Singh, Satish Kumar, additional, Singhal, Rajesh Kumar, additional, Skalicky, Milan, additional, Syed, M. Abu, additional, Syed, Tahira, additional, Tabassum, Javaria, additional, Thakkar, Shalini, additional, Thangjam, Rojeet, additional, Trivedi, Ankita, additional, Ul-Allah, Sami, additional, Yousaf, Muhammad Irfan, additional, and Zafar, Syed Adeel, additional

Published
2022
Full Text
View/download PDF

35. Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma

Author

Alkhateeb, Hassan B., Mohty, Razan, Greipp, Patricia, Bansal, Radhika, Hathcock, Matthew, Rosenthal, Allison, Murthy, Hemant, Kharfan-Dabaja, Mohamed, Bisneto Villasboas, Jose C., Bennani, Nora, Ansell, Stephen M., Patnaik, Mrinal M., Litzow, Mark R., He, Rong, Chen, Dong, Al-Kali, Aref, Kenderian, Saad S., Lin, Yi, and Shah, Mithun Vinod

Published
2022
Full Text
View/download PDF

37. Temperature-Dependent Characteristics of GeSn Waveguide p-i-n Photodetectors: Step Towards Cryogenic Silicon Photonics

Author

Bansal, Radhika, Jheng, Yue-Tong, Lee, Kuo-Chih, Wen, Shuyu, Berencen, Yonder, Cheng, Hung-Hsiang, and Chang, Guo-En

Abstract

GeSn waveguide photodetectors (WGPDs) that function in the 2-µm band have been considered potentially competitive candidates for cryogenic silicon photonics to enable various emerging applications such as quantum sensing and quantum computing. Herein, we present a high-performance GeSn rib WGPD that can function within the 2-µm spectral range and its temperature-dependent characteristics. The proposed detectors feature a GeSn active layer with 4.9% Sn which redshifts the cutoff wavelength to cover the 2-µm band. In addition, the optical confinement factor was enhanced by growing a thick GeSn active layer. This resulted in a room temperature responsivity of 0.224 A/W at $\lambda = \text{1900 nm}$. We measured a noise equivalent power of $9.5 \times {{10}^{ - 10}}\ \mathrm{W}/\mathrm{H}{{\mathrm{z}}^{1/2}}$ at $\lambda = \text{1550 nm}$, confirming the practical viability of the proposed detector. Moreover, the temperature-dependent characteristics indicate that the dark current density (${{J}_{{\rm{dark }}}}$) variation is extremely low and responsivity decreases at low temperatures, leading to decreased spectral detectivity (${{D}^*}$), whereas the cut-off wavelength (${{\lambda }_{\mathrm{c}}}$) blueshifts owing to the increased bandgap. The temperature-dependent characteristics of the proposed GeSn WGPDs are expected to advance the understanding of GeSn WGPDs for cryogenic silicon photonics.

Published
2025
Full Text
View/download PDF

39. Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clinic experience.

Author

Chohan, Karan L., Bansal, Radhika, Hathcock, Matthew A., Paludo, Jonas, Bennani, Nora N., Johnston, Patrick B., Khurana, Arushi, Durani, Urshila, Wang, Yucai, Ruff, Michael W., Villasboas Bisneto, Jose C., Ansell, Stephen M., Lin, Yi, and Kenderian, Saad S.

Subjects
*CYTOKINE release syndrome, *DIFFUSE large B-cell lymphomas, *CHIMERIC antigen receptors, *CUTANEOUS T-cell lymphoma, *T cells
Abstract

A study conducted at the Mayo Clinic examined the association between cytokine release syndrome (CRS) and neurotoxicity (NT) with the efficacy of anti-CD-19 chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma. The study found that CRS and NT were common adverse events associated with CAR-T therapy, and there was a significant association between the presence of CRS and NT. However, the study also noted that the relationship between efficacy and toxicity was complex and further investigation is needed. The study analyzed patient data from 113 individuals treated with CAR-T therapy at the Mayo Clinic. This study examined the association between therapy response, toxicity, and survival outcomes in patients with aggressive lymphoma treated with CAR-T cell therapy. The results showed that while CRS and NT were associated with improved treatment-related efficacy outcomes, they were not necessary for therapeutic efficacy. Patients with low-grade CRS had better overall survival outcomes compared to those with no CRS or high-grade CRS. The study suggests that future CAR-T cell therapy development should focus on maximizing disease response while minimizing adverse events. [Extracted from the article]

Published
2024
Full Text
View/download PDF

40. POSTER: ABCL-673 Single Cell Analysis Reveals Immune Dysfunction in Large B-Cell Lymphoma (LBCL) Patients With Hypomagnesemia Receiving Axi-Cel: Results from ZUMA-1 Trial and Mayo Clinic Cohort

Author

Mondello, Patrizia, primary, Gile, Jennifer, additional, Wang, Zixing, additional, Li, Ying, additional, Bansal, Radhika, additional, Gandhi, Sangeetha, additional, Zhang, Henan, additional, Babadi, Elham, additional, Martinez, Kodi, additional, McCoy, Gabrielle, additional, Shao, Zuoyi, additional, Regan, Keven, additional, Hathcock, Matthew, additional, Wang, Panwen, additional, Wang, Wang, additional, Al Saleh, Abdullah, additional, Ruan, Gordon, additional, Yang, Zhi Zhang, additional, Paludo, Jonas, additional, Villasboas, Jose, additional, Khurana, Arushi, additional, Durani, Urshila, additional, Wang, Yucai, additional, Hampel, Paul, additional, Rosenthal, Allison, additional, Munoz, Javier, additional, Moreno, Eider, additional, Castro, Januario, additional, Murthy, Murthy, additional, Kharfan-Dabaja, Mohamed, additional, Kenderian, Saad, additional, Mattie, Mike, additional, Bot, Adrian, additional, Rossi, John, additional, Witzig, Thomas, additional, and Lin, Yi, additional

Published
2023
Full Text
View/download PDF

41. P-003 Clinical outcomes among multiple myeloma and lymphoma patients taking beta-blockers undergoing CAR-T therapy

Author

Balandan, Kristina, primary, Hwa, Yi, additional, Bansal, Radhika, additional, Khurana, Arushi, additional, Johnston, Patrick, additional, Ansell, Stephen, additional, Bennani, Nora, additional, Binder, Moritz, additional, Dingli, David, additional, Gertz, Morie, additional, Haymann, Suzanne, additional, Kapoor, Prashant, additional, Kourelis, Taxiarchis, additional, Kumar, Shaji, additional, Paludo, Jonas, additional, Warsame, Rahma, additional, Wang, Yucai, additional, Cook, Joselle, additional, Durani, Urshila, additional, Lin, Yi, additional, and Dispenzieri, Angela, additional

Published
2023
Full Text
View/download PDF

42. MM-527 Real World Evaluation of Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM)

Author

Maringanti, Sireesha Asoori, primary, Lin, Yi, additional, Estritis, Stathis, additional, Martinez-Lopez, Joaquin, additional, Bansal, Radhika, additional, Fotiou, Despina, additional, Corona, Magdalena, additional, Chhabra, Saurabh, additional, Brunaldi, Larissa, additional, Corraes, Andre De Menezes Silva, additional, Parrondo, Ricardo, additional, Kapoor, Prashant, additional, Ailawadhi, Sikander, additional, Mas, Reyes, additional, Tamayo, Andrea, additional, Dimopoulos, Meletios, additional, Durie, Brian, additional, and Martin, Thomas, additional

Published
2023
Full Text
View/download PDF

43. P-049 Safety and efficacy of standard of care ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM): real world experience

Author

Sidana, Surbhi, primary, Patel, Krina, additional, Peres, Lauren, additional, Bansal, Radhika, additional, Kocoglu, M Hakan, additional, Shune, Leyla, additional, Atrash, Shebli, additional, Smith, Kinaya, additional, Ferreri, Christopher, additional, Dhakal, Binod, additional, Chhabra, Saurabh, additional, Parrondo, Ricardo, additional, Costello, Patrick, additional, Midha, Shonali, additional, Martin, Thomas, additional, Simmons, Gary, additional, Alsina, Melissa, additional, Htut, Myo, additional, Voorhees, Peter, additional, Sborov, Douglas, additional, Khouri, Jack, additional, Wong, Sandy, additional, Janakiram, Murali, additional, Lin, Yi, additional, and Hansen, Doris, additional

Published
2023
Full Text
View/download PDF

44. POSTER: MM-527 Real World Evaluation of Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM)

Author

Maringanti, Sireesha Asoori, primary, Lin, Yi, additional, Estritis, Stathis, additional, Martinez-Lopez, Joaquin, additional, Bansal, Radhika, additional, Fotiou, Despina, additional, Corona, Magdalena, additional, Chhabra, Saurabh, additional, Brunaldi, Larissa, additional, De Menezes Silva Corraes, Andre, additional, Parrondo, Ricardo, additional, Kapoor, Prashant, additional, Ailawadhi, Sikander, additional, Mas, Reyes, additional, Tamayo, Andrea, additional, Dimopoulos, Meletios, additional, Durie, Brian, additional, and Martin, Thomas, additional

Published
2023
Full Text
View/download PDF

45. ABCL-673 Single Cell Analysis Reveals Immune Dysfunction in Large B-Cell Lymphoma (LBCL) Patients With Hypomagnesemia Receiving Axi-Cel: Results from ZUMA-1 Trial and Mayo Clinic Cohort

Author

Mondello, Patrizia, primary, Gile, Jennifer, additional, Wang, Zixing, additional, Li, Ying, additional, Bansal, Radhika, additional, Gandhi, Sangeetha, additional, Zhang, Henan, additional, Babadi, Elham, additional, Martinez, Kodi, additional, McCoy, Gabrielle, additional, Shao, Zuoyi, additional, Regan, Keven, additional, Hathcock, Matthew, additional, Wang, Panwen, additional, Wang, Wang, additional, Al Saleh, Abdullah, additional, Ruan, Gordon, additional, Yang, Zhi Zhang, additional, Paludo, Jonas, additional, Villasboas, Jose, additional, Khurana, Arushi, additional, Durani, Urshila, additional, Wang, Yucai, additional, Hampel, Paul, additional, Rosenthal, Allison, additional, Munoz, Javier, additional, Moreno, Eider, additional, Castro, Januario, additional, Murthy, Murthy, additional, Kharfan-Dabaja, Mohamed, additional, Kenderian, Saad, additional, Mattie, Mike, additional, Bot, Adrian, additional, Rossi, John, additional, Witzig, Thomas, additional, and Lin, Yi, additional

Published
2023
Full Text
View/download PDF

46. S263: CYTOPENIAS, AGE AND CAR-HEMATOTOX SCORE PREDICT THE DEVELOPMENT OF POST CAR T-CELL THERAPY-RELATED MYELOID NEOPLASMS

Author

Gurney, Mark, primary, Alkhateeb, Hassan, additional, Shah, Syed, additional, Bansal, Radhika, additional, Hathcock, Matthew, additional, Rosenthal, Allison, additional, Kharfan-Dabaja, Mohamed, additional, Kourelis, Taxiarchis, additional, Patnaik, Mrinal, additional, Chen, Dong, additional, Al-Kali, Aref, additional, Kenderian, Saad, additional, Lin, Yi, additional, and Shah, Mithun, additional

Published
2023
Full Text
View/download PDF

49. Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma

Author

Saifi, Omran, primary, Breen, William G, additional, Lester, Scott C, additional, Rule, William G, additional, Stish, Bradley J, additional, Rosenthal, Allison, additional, Munoz, Javier, additional, Lin, Yi, additional, Bansal, Radhika, additional, Hathcock, Matthew A, additional, Johnston, Patrick B, additional, Ansell, Stephen M, additional, Paludo, Jonas, additional, Khurana, Arushi, additional, Villasboas, Jose C, additional, Wang, Yucai, additional, Iqbal, Madiha, additional, Moustafa, Muhamad Alhaj, additional, Murthy, Hemant S, additional, Kharfan-Dabaja, Mohamed A., additional, Peterson, Jennifer L, additional, and Hoppe, Bradford S, additional

Published
2023
Full Text
View/download PDF

50. Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy

Author

Bezerra, Evandro D., primary, Iqbal, Madiha, additional, Munoz, Javier, additional, Khurana, Arushi, additional, Wang, Yucai, additional, Maurer, Matthew J., additional, Bansal, Radhika, additional, Hathcock, Matthew A., additional, Bennani, Nora, additional, Murthy, Hemant S., additional, Rosenthal, Allison C., additional, Paludo, Jonas, additional, Villasboas, Jose C., additional, Johnston, Patrick B., additional, Habermann, Thomas M., additional, Ansell, Stephen M., additional, Castro, Januario E., additional, Witzig, Thomas E., additional, Kharfan-Dabaja, Mohamed A., additional, Nowakowski, Grzegorz S., additional, and Lin, Yi, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results